Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DDIPI

Financiado

Cerrado

Drug Discovery in Interacting Proteins

The Pharmaceutical sector is a mainstay of the European economy. However, changing patterns of drug discovery and competition has greatly enhanced the need for a SME sector to produce new drug leads and targets to feed big Pharma... ver más

31/07/2014

NUIM

643K€

Presupuesto del proyecto: 643K€

Líder del proyecto

NATIONAL UNIVERSITY OF IRELAND MAYNOOTH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

NUIM

0.00€ | Lider

Dualsystems Biotech AG

N.D. | Participante

AFCP

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

NATIONAL UNIVERSITY OF IRELAND MAYNOOTH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 643K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Pharmaceutical sector is a mainstay of the European economy. However, changing patterns of drug discovery and competition has greatly enhanced the need for a SME sector to produce new drug leads and targets to feed big Pharma pipelines. This application addresses the need by coalescing partners involved in the identification/validation of new targets and in drug design, synthesis and discovery. The focus is on type 2 diabetes, obesity and immune diseases which cause serious disability and reduced life expectancy globally. Dualsystems and NUIM will be involved in the identification/validation of protein interactions involved in the pathway linking retinol binding protein and insulin, through which the former, when elevated in obesity, inhibits responses to the latter thereby contributing to type 2 diabetes. A second project will identify the protein machinery involved in the failure of otherwise active natural mutants of the MC4 receptor to traffic to the cell surface. This failure produces 6-7% of cases of gross genetic obesity. The third project will identify native protein ligands for a new family of G-protein coupled receptors (LNB-GPCRs), deeply implicated in immune-related diseases and cancer. The transfer of knowledge (TOK) involve development and use of yeast 2-hybrid systems to identify putative interactors and of rapid in vitro systems for interacting protein validation. A new yeast-based biosensor system will be advanced from proof of concept to the development stage. AFChemPharm focuses on new systems of chemical synthesis. They will work with NUIM on protein modelling, drug design, in silico screening and chemical synthesis to produce selected panels of compounds to screen for hits and to optimise into leads. The TOK and skills acquisition will involve state of the art computational approaches in modelling, drug design and screening, together with their amalgamation with new synthetic processes to tailor/refine design and synthesis.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores